News | October 17, 2022
Biocon Biologics signs licensing agreement with Yoshindo
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
The requirement of blood in India is estimated to be 8.5 million to 10 million units/per year, whereas the available supply is only 7.4 million units/per year
New material distribution will serve medical device and pharmaceutical packaging manufacturers.
Plans to double its manufacturing footprint to bolster the growth
-0001_256_384.jpg){kind=logo}
The eyecirque under eye skin brightening supplement is a unique composition of scientifically proven essential antioxidants, vitamins and minerals
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
The company increases its efficiency and is able to face the growing demand for its services.
DSCO has requested WHO to share at the earliest with CDSCO the report on establishment of causal relation to death with the medical products in question etc.
This acquisition will accelerate Medcare's plans to emerge as an international hub for health, beauty, and wellness adding to its existing network of 4 hospitals and over 20 medical centres in the UAE.
Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion
Subscribe To Our Newsletter & Stay Updated
